Roots Analysis is pleased toannounce the publication of its recent study, titled, “Bispecific AntibodyTherapeutics Market (4th Edition),2020-2030.”
The report featuresan extensive study of the current market landscape, offering an informedopinion on the likely adoption of these therapeutics over the next decade. Thestudy features an in-depth analysis, highlighting the capabilities of variousstakeholders engaged in this domain. Amongst other elements, the reportincludes:
§ A detailed assessmentof the current market landscape of drug developers engaged in the developmentof bispecific antibody therapeutics.
§ A comprehensive analysisof novel technology platforms that are either currently available or beingdeveloped for the generation of bispecific antibody therapeutics.
§ Detailed profiles of marketedand clinical stage (phase II and phase III) bispecific antibody therapeutics.
§ Key takeaways fromthe bispecific antibody therapeutics pipeline.
§ An analysis of theinitiatives of big biopharma players engaged in this domain.
§ An analysis of recentpartnerships and collaboration agreements inked in bispecific antibodytherapeutics domain.
§ A review on the keysteps involved and challenges associated with the manufacturing of bispecificantibodies.
§ A clinical trialanalysis of ongoing and planned studies related to bispecific antibodytherapeutics.
§ A review of the key promotionalstrategies that have been adopted by the developers of the marketed bispecificantibodies.
§ A discussion onimportant, industry-specific trends, key market drivers and challenges, under aSWOT framework.
§ A detailed marketforecast, featuring analysis of the current and projected future opportunityacross key market segments (listed below)
- Target Disease Indication
§ Autoimmune Disorders
§ Eye Disorders
§ Genetic Disorders
§ HematologicalMalignancies
§ Infectious Diseases
§ InflammatoryDisorders
§ Skin Disorders
- Mechanism of Action
§ Cytokines Retargeting/ Neutralization
§ Dual Ligands Blocking
§ T-cell Retargeting /Activation
§ Others
- Target Antigens
§ CD3 x CD19
§ CD30 x CD16A
§ Factor IXa x Factor X
§ IL-1α x IL-1β
§ IL-13 x IL-4
§ IL-17A x Albumin
§ IL-17A x IL-17F
§ Psl x PcrV
§ TNF-α x HAS
§ VEGF-A x ANG2
§ Others
- Antibody Format
§ Asymmetric
§ Fragments
§ Symmetric
§ Others
- Key Geographical Region
§ North America
§ Europe
§ Asia-Pacific
Transcripts of interviews heldwith the following senior level representatives of stakeholder companies:
§ Martin Steiner (ChiefExecutive Officer, Synimmune)
§ Ludger Große-Hovest(Chief Scientific Officer, Synimmune)
§ Jane Dancer (ChiefBusiness Officer, F-Star)
§ Siobhan Pomeroy(Senior Director, Business Development, Cytom X)
§ Yinjue Wang(Associate Director, Process Development, Innovent Biologics)
Key companies covered in the report
§ Amgen
§ Ablynx
§ AbbVie
§ Affibody
§ Affimed
§ Alphamab
§ AstraZeneca
§ Avillion
§ ChugaiPharmaceuticals
§ Eddingpharm
§ GSK
§ Merck
§ Merus
§ Roche
§ RegeneronPharmaceuticals
§ TaishoPharmaceuticals
§ Zymeworks
For more information pleaseclick on the following link:
https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html
Other RecentOfferings
1. Global Preventive VaccinesMarket, 2020-2030
2. Endocannabinoid SystemTargeted TherapeuticsMarket, 2019-2030
3. Antibody ContractManufacturing Market,2020-2030
About Roots Analysis
Roots Analysis is oneof the fastest growing market research companies, sharing fresh and independentperspectives in the bio-pharmaceutical industry. The in-depth research,analysis and insights are driven by an experienced leadership team which hasgained many years of significant experience in this sector. If you’d like helpwith your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots AnalysisPrivate Limited
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
